ClinicalTrials.gg
RecruitingNCT07388394POLYVIHUpdated Oct 29, 2026

Polypharmacy on Healthy Aging in People Living With HIV Over the Age of 75

An interventional study of interview with advanced practice nurse in Virus-HIV, sponsored by Centre Hospitalier Universitaire de Nice. Recruiting at 1 site in France. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Oct 29, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
136
Allocation
Not applicable
Ages
75 Years and older
Sex
All
01

Study summary

Since the advent of antiretroviral treatments, the life expectancy of people living with HIV (PLHIV) has increased significantly. In France, more than 30% of PLHIV are now over 50 years old. This population is exposed to high multimorbidity, leading to frequent polypharmacy, defined as the regular use of at least five medications. Polypharmacy also has a qualitative dimension, including potentially inappropriate prescriptions. It increases the risk of adverse effects and drug interactions and impairs quality of life. A coordinated geriatric approach is therefore essential to optimize care. Healthy aging, promoted by the WHO, aims to improve the lives of older people. In this context, a study will be conducted at the Nice University Hospital among PLHIV aged 75 and over. It will collect quantitative data, the results of which will enable us to consider, if necessary, adapting the care pathways of these patients whose needs are complex.

02

Conditions studied

  • Virus-HIV

Browse trials for

03

In context

Acquired Immunodeficiency Syndrome Unverified

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's planned enrollment of 136 is above the median of 96 across 2,254 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Centre Hospitalier Universitaire de Nice is the lead sponsor of 725 studies on the registry; 177 are open to participants now.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -positive
  • Aged 75 or over
  • Affiliated with the social security system
  • Having expressed no objection to participating in the study

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate
  • Known severe cognitive impairment preventing the interview from being conducted
  • Patient under guardianship or conservatorship
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
136 participants (estimated)

Study arms

  • Other
    people living with HIV over the age of 75

    Other: interview with advanced practice nurse

Interventions

  • Otherinterview with advanced practice nurse

    45 to 60 minutes of interview

06

What researchers measure

Primary outcomes

  1. Describe polypharmacy among people living with HIV aged 75 and older.

    The average number of medications taken

    Time frame: 18 months

Secondary outcomes

  1. Assess the most common comorbidities associated with polypharmacy in the population of PLHIV aged 75

    Number et type of comorbidities

    Time frame: 18 months

  2. Assess whether people taking multiple medications have a lower treatment adherence score than those taking fewer medications.

    Score obtained on the Morisky MMAS-8 questionnaire

    Time frame: 18 months

  3. Assess the level of functional independence in this age group and link it to the existence of polypharmacy.

    Lawton and Brody IADL scale

    Time frame: 18 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2027, 19 months after the start.

Of 642 non-industry interventional studies with no phase under Acquired Immunodeficiency Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's planned 19 months is below that.

Counting every sponsor, half of 648 studies reached it within 29 months; a quarter within 17 and three quarters within 45.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion May 2027 → Aug 2027 and completion May 2027 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2026
First posted
Feb 5, 2026
StartActual
Jan 28, 2026
Primary completionEst.
Aug 31, 2027was May 2027
CompletionEst.
Aug 31, 2027was May 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Recruiting Reason for stopping removed
changed Oct 29, 2026
Sites
CHU de NICE is now Recruiting
Oct 29, 2026
Primary completion
May 31, 2027→Aug 31, 2027
Oct 29, 2026
Study completion
May 31, 2027→Aug 31, 2027
Oct 29, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameDescribe polypharmacy among people living with HIV aged 75 and older.15 months → 18 months
Oct 29, 2026
Secondary outcomes
3 time frame changed
What changed in the outcomes
  • Time frameAssess the most common comorbidities associated with polypharmacy in the population of PLHIV aged 7515 months → 18 months
  • Time frameAssess whether people taking multiple medications have a lower treatment adherence score than those taking fewer medications.15 months → 18 months
  • Time frameAssess the level of functional independence in this age group and link it to the existence of polypharmacy.15 months → 18 months
Oct 29, 2026
Contact
Study contact now listed: added b•••@chu-nice.fr · •••5467; added T•••@chu-nice.fr. See the current contact
Oct 29, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • CHU de NICE · Nice, FranceContact added B•••@chu-nice.fr · •••5467Contact added T•••@chu-nice.fr
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Suspended→Recruiting
    Why stopped Reason for stopping removed
    CHU de NICE is now Recruiting
    Primary completion May 31, 2027→Aug 31, 2027
    Study completion May 31, 2027→Aug 31, 2027
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameDescribe polypharmacy among people living with HIV aged 75 and older.15 months → 18 months
    Secondary outcomes 3 time frame changed
    What changed in the outcomes
    • Time frameAssess the most common comorbidities associated with polypharmacy in the population of PLHIV aged 7515 months → 18 months
    • Time frameAssess whether people taking multiple medications have a lower treatment adherence score than those taking fewer medications.15 months → 18 months
    • Time frameAssess the level of functional independence in this age group and link it to the existence of polypharmacy.15 months → 18 months
    Contact Study contact now listed: added b•••@chu-nice.fr · •••5467; added T•••@chu-nice.fr. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • CHU de NICE · Nice, FranceContact added B•••@chu-nice.fr · •••5467Contact added T•••@chu-nice.fr
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07388394
Responsible party
Sponsor
First posted
Feb 5, 2026
Start date
Jan 28, 2026
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Lysandre BLANCKEMAN
Contact
blanckerman.l@chu-nice.fr
04 92 03 54 67
Irit TOUITOU
Contact
Touitou.i@chu-nice.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion